NPJ vaccinesMay 5, 2026

Single- and multiple-target OspA mRNA vaccines produce protective antibodies against Lyme disease bacteria in mice

mRNA Technology Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Jun 27, 2026

Abstract

Essence

OspA mRNA-LNP vaccines generated functional anti-Borrelia antibodies and protected mice from tick-mediated infection.

Evidence

This preclinical vaccine study used structural and antibody-binding assays, mouse immunization, in vitro agglutination and borreliacidal tests, and tick-mediated B. burgdorferi challenge with monovalent ST1 and heptavalent OspA mRNA-LNP formulations.

Caveat

Protection was shown in mice, while the monovalent and heptavalent vaccines are only described as entering Phase 1 human testing.

Simplified

Outer surface protein A (OspA) is a ~30 kDa lipoprotein displayed on the surface of Borrelia burgdorferi sensu lato, the etiological agent of Lyme disease. Here we report on the preclinical evaluation of OspA-encoding nucleoside-modified mRNA lipid nanoparticle (OspA mRNA-LNP) vaccines for the prevention of Lyme disease. Crystallographic and binding studies using a panel of transmission-blocking antibodies confirmed that the mRNA-encoded OspA serotype 1 (ST1) expressed in mammalian cells assumes its native structure and retains known protective epitopes. Immunization of mice with OspA ST1 mRNA-LNP elicited functional serum antibodies that promoted spirochete agglutination and complement-dependent borreliacidal activity in vitro. We also examined the impact of combining ST1 OspA mRNA with OspA STs 2-7, which are associated with predominant Borrelia genospecies in Europe (B. garinii, B. afzelii, and B. bavariensis). The additional six STs mRNA did not interfere with ST1 antibody titers and functionality. Finally, mice vaccinated two or three times with different dose levels of OspA ST1 mRNA-LNP or with the heptavalent mRNA vaccine were protected against B. burgdorferi infection in a tick-mediated challenge model. The monovalent and the heptavalent OspA mRNA vaccines (mRNA-1982 and mRNA-1975, respectively) are currently undergoing testing in a Phase 1 clinical trial (NCT05975099).

Full Text

Full text is available at the source.

View Full Text ↗

Featured in

mRNA TechnologyIssue #36

Fractalkine-targeted mRNA nanoparticles hit 95% of killer T cells in mice

↗

Single- and multiple-target OspA mRNA vaccines produce protective antibodies against Lyme disease bacteria in mice

Abstract

Full Text

Featured in

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the mrna technology brief